Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-27T10:49:29.061Z Has data issue: false hasContentIssue false

Carbamazepine-induced toxidermia: Case report and a literature review

Published online by Cambridge University Press:  27 August 2024

R. Jbir*
Affiliation:
Psychiatry C department, Hedi chaker university hospital, Sfax, Tunisia
M. maalej
Affiliation:
Psychiatry C department, Hedi chaker university hospital, Sfax, Tunisia
S. Omri
Affiliation:
Psychiatry C department, Hedi chaker university hospital, Sfax, Tunisia
N. Charfi
Affiliation:
Psychiatry C department, Hedi chaker university hospital, Sfax, Tunisia
R. Feki
Affiliation:
Psychiatry C department, Hedi chaker university hospital, Sfax, Tunisia
I. Gassara
Affiliation:
Psychiatry C department, Hedi chaker university hospital, Sfax, Tunisia
N. Smaoui
Affiliation:
Psychiatry C department, Hedi chaker university hospital, Sfax, Tunisia
L. Zouari
Affiliation:
Psychiatry C department, Hedi chaker university hospital, Sfax, Tunisia
J. Ben Thabet
Affiliation:
Psychiatry C department, Hedi chaker university hospital, Sfax, Tunisia
M. Maalej
Affiliation:
Psychiatry C department, Hedi chaker university hospital, Sfax, Tunisia
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Carbamazepine is effectively used in treatment of bipolar disorder for its thymoregulatory virtues, but it can induce numerous side effects, including skin eruptions that can be severe sometimes.

Objectives

To study the relationship between toxidermia and treatment with carbamazepine.

Methods

We report the case of a patient who developed a toxidermia following the intake of carbamazepine.

Results

Mr. AD, 19 years old, with medical history of diabetes, has been diagnosed with bipolar disorder since the age of 17. He was initially treated with risperidone with an irregular follow-up.

He was hospitalized in our department for a manic episode with psychotic features with agitation and refusal of treatment.

The patient was put on injectable treatment 15 mg/day of Haloperidol and 20 mg/day of diazepam.

After 5 days in hospital, we switched to the oral route, gradually increasing haloperidol doses to 30mg, reducing diazepam doses and introducing carbamazepine for thymoregulatory purposes.

Carbamazepine was progressively increased up to a dose of 800mg per day.

Fourteen days after the introduction of carbamazepine, the patient presented a generalized rash requiring the discontinuation of this medication. He was treated with an anti-histamine and local corticosteroids, on the advice of dermatologists.

In the days following discontinuation of carbamazepine, skin lesions regress and then disappear.

Biologically, we observed a rise in eosinophilic polynuclear cells to 580, followed by a gradual decrease after stopping the treatment.

A pharmacovigilance opinion was sought, concluding that carbamazepine was responsible for the toxidermia, given the delay in onset and the favorable evolution after discontinuation of the incriminating treatment. Moreover, this undesirable effect is well described in the literature.

Hence the contraindication to further use of carbamazepine in Mr. AD.

In addition, the patient was put on sodium valproate with good tolerance.

Conclusions

Each prescribed drug must be considered as potentially capable of causing cutaneous reactions as an adverse effect. Both the prescriber and the patient must be made aware of this phenomenon. The attitude can be modulated on a case-by-case basis, after specialist advice, depending on the severity of the rash and the disease to be treated.

Disclosure of Interest

None Declared

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.